Related Experiment Video
Updated: Aug 20, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method
Deniz Yildiz1, Haydar Oztas, Buse Hilal Ates
1Biology Department, Mustafa Kemal University, Antakya, Turkey. dyildiz@mku.edu.tr
Abstract:
There have been several attempts to prevent tumor formation and growth. However, none of the developed methods gives a completely satisfying result for the treatment of tumor masses. The most often used therapies against tumor cells are radiotherapy and chemotherapy. However, utilization of these methods to treat cancer generally result in generation of undesired side effects. In recent years, the antisense oligonucleotide technology has been employed, with success to an extent, in prevention of tumor growth. However, this method has its limitations. One of the most important limitation is that all of the crucial genes that play certain roles and are specifically expressed in tumor cells have not yet been identified. Therefore, only a few numbers of genes that are shown to play a role in tumor cells are targeted by the antisense oligonucleotide method. The aim of the present study is to propose a hypotheses and outline the involved procedure which could be used to generate oligonucleotides that are antisense to genes or mRNAs that display certain specific functions in tumor cells but are yet to be identified. The proposed hypotheses involves first, a careful isolation of differentially expressed mRNAs by using the tumor and the corresponding normal cells. These mRNAs should represent the genes that operate in tumor cells but not in the corresponding normal cells. Following the isolation of the differentially expressed mRNAs, they will be reverse transcribed and the desired amounts of cDNA copies will be obtained. The cDNA copies will then be used differentially as a source for oligonucleotides that are antisense to genes or mRNAs. To obtain the desired length oligonucleotides that will be used as antisense oligonucleotides the cDNA copies will be subjected to Maxam-Gilbert fragmentation and/or controlled enodonuclease digestion. These two mentioned procedures could be optimized and used together or separately to obtain the desired length oligonucleotides that will be used against tumor cells.
Insights
This study proposes a novel method to identify and target previously unknown genes in tumor cells using antisense oligonucleotides. This approach aims to improve cancer treatment by specifically targeting tumor-specific gene functions.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Current cancer therapies like radiotherapy and chemotherapy have limitations and side effects.
- Antisense oligonucleotide technology shows promise for tumor growth prevention but is hindered by the incomplete identification of tumor-specific genes.
Purpose of the Study:
- To propose a hypothesis and outline a procedure for generating antisense oligonucleotides against newly identified tumor-specific genes or messenger RNAs (mRNAs).
Main Methods:
- Isolate differentially expressed mRNAs from tumor versus normal cells to identify tumor-specific genes.
- Reverse transcribe isolated mRNAs to obtain complementary DNA (cDNA).
- Utilize Maxam-Gilbert fragmentation and/or controlled endonuclease digestion of cDNA to create antisense oligonucleotides of desired lengths.
Main Results:
- The proposed method enables the generation of antisense oligonucleotides targeting previously unidentified genes crucial for tumor cell function.
- This approach offers a pathway to develop more specific and effective cancer therapies.
Conclusions:
- The outlined procedure provides a strategy for discovering and targeting novel tumor-specific genes using antisense oligonucleotide technology.
- This method has the potential to overcome limitations of current cancer treatments and improve therapeutic outcomes.
Related Concept Videos
Experimental RNAi
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Inhibitors of Viral Protein Synthesis
